Enliven Therapeutics (ELVN) vs Zai Lab (ZLAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Enliven Therapeutics (ELVN) has outperformed Zai Lab (ZLAB) over the past year, gaining 100.0% versus a loss of 26.4%. Over five years, ELVN leads with a +177.5% price change compared with -75.7% for ZLAB. Enliven Therapeutics is the larger company by market cap ($2.97 billion vs $2.79 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELVN | ZLAB |
|---|---|---|
| Share price | $40.53 | $24.82 |
| Market cap | $2.97B | $2.79B |
| 1-day change | -0.26% | +0.04% |
| YTD return | +163.83% | +40.65% |
| 1-year return | +99.95% | -26.36% |
| 5-year return | +177.53% | -75.68% |
| EPS (TTM) | $-1.67 | $-1.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $460.16M |
| Revenue growth (YoY) | — | +15.33% |
| Net income (latest FY) | $-103.69M | $-175.54M |
| Gross margin | — | 58.60% |
| Operating margin | — | -49.86% |
| Net margin | — | -38.15% |
| 52-week high | $62.32 | $32.76 |
| 52-week low | $14.79 | $15.96 |
| Distance from 52-week high | -34.97% | -24.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +81.79% | +33.52% |
| Average volume | 1.13M | 945.51K |
| Shares outstanding | 73.27M | 112.27M |
| Employees | 67 | 1,784 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELVN has outperformed ZLAB by 126.3 percentage points over the past year.
About Enliven Therapeutics
ELVN stock →Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
About Zai Lab
ZLAB stock →Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees
ELVN vs ZLAB FAQ
Which is bigger, Enliven Therapeutics or Zai Lab?
Enliven Therapeutics (ELVN) is larger, with a market capitalization of $2.97B compared with $2.79B for Zai Lab (ZLAB).
Which stock has performed better over the past year, ELVN or ZLAB?
ELVN returned +99.95% over the past 12 months, compared with -26.36% for ZLAB (price return, excluding dividends). Past performance does not predict future results.
Are Enliven Therapeutics and Zai Lab in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.